feed,title,long_url,short_url
MedRxiv,"Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial",https://medrxiv.org/cgi/content/short/2022.08.09.22278560v1?rss=1,https://bit.ly/3JTir55
MedRxiv,An evaluation of the early impact of the COVID-19 pandemic on Zambia's routine immunization program,https://medrxiv.org/cgi/content/short/2022.08.12.22278710v1?rss=1,https://bit.ly/3dxOoE4
MedRxiv,Risk factors for COVID-19 hospitalization or death during the first Omicron surge in adults: a large population-based case-control study,https://medrxiv.org/cgi/content/short/2022.08.11.22278682v1?rss=1,https://bit.ly/3PmAcus
MedRxiv,Estimation of the Total Number of Infected Cases in the 5th Wave of COVID-19 in Hong Kong,https://medrxiv.org/cgi/content/short/2022.08.12.22278708v1?rss=1,https://bit.ly/3dw2aqo
